Shares of Recursion Pharmaceuticals, Inc. (RXRX) plummeted 5.06% in intraday trading on Monday, following the company's disappointing fourth-quarter 2024 financial results.
The biopharmaceutical company focused on decoding biology to radically improve lives reported an adjusted loss per share of $0.81, significantly wider than the Zacks Consensus Estimate of $0.36 loss per share.
The wider-than-expected loss appears to be the primary driver behind the stock's sharp decline, as investors reacted negatively to the company's lackluster performance during the quarter.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.